thiosulfates has been researched along with Deafness, Transitory in 20 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses." | 9.27 | Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. ( Ansari, M; Brichard, B; Brock, PR; Brugières, L; Capra, M; Childs, M; Covezzoli, A; Czauderna, P; Dall'Igna, P; Hiyama, E; Laithier, V; Maibach, R; Mateos, ME; Morland, B; Neuwelt, EA; Perilongo, G; Rajput, K; Rangaswami, AA; Rechnitzer, C; Roebuck, D; Ronghe, M; Skeen, J; Sullivan, MJ; Veal, GJ, 2018) |
| "Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin." | 9.24 | Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. ( Bliss, B; Chen, L; Freyer, DR; Knight, K; Krailo, MD; Lange, B; Neuwelt, EA; Pollock, BH; Ramdas, J; Sung, L; Van Hoff, D; VanSoelen, ML; Villaluna, D; Wiernikowski, J, 2017) |
| "To determine safety, feasibility, and preliminary activity of transtympanic injection of sodium thiosulfate (STS) against cisplatin-induced hearing loss (CIHL)." | 5.41 | Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial. ( Balm, AJM; Beijnen, JH; Burgers, JA; de Boer, JP; de Weger, VA; Dreschler, WA; Duinkerken, CW; Hauptmann, M; Marchetti, S; Nuijen, B; Pluim, D; Rosing, H; Schellens, JHM; van der Molen, L; Zuur, CL, 2021) |
| "Sodium thiosulfate (STS) has been described as a protective agent against CDDP toxicity, but it also reduces CDDP's antitumoral cytotoxicity." | 5.32 | Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. ( Fetoni, A; Guitton, MJ; Lloyd Faulconbridge, RV; Puel, JL; Pujol, R; Wang, J, 2003) |
| "We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses." | 5.27 | Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. ( Ansari, M; Brichard, B; Brock, PR; Brugières, L; Capra, M; Childs, M; Covezzoli, A; Czauderna, P; Dall'Igna, P; Hiyama, E; Laithier, V; Maibach, R; Mateos, ME; Morland, B; Neuwelt, EA; Perilongo, G; Rajput, K; Rangaswami, AA; Rechnitzer, C; Roebuck, D; Ronghe, M; Skeen, J; Sullivan, MJ; Veal, GJ, 2018) |
| "Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin." | 5.24 | Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. ( Bliss, B; Chen, L; Freyer, DR; Knight, K; Krailo, MD; Lange, B; Neuwelt, EA; Pollock, BH; Ramdas, J; Sung, L; Van Hoff, D; VanSoelen, ML; Villaluna, D; Wiernikowski, J, 2017) |
| " We aimed to compare the incidence of hearing loss between patients treated with intra-arterial high-dose cisplatin chemoradiation with sodium thiosulfate (CRT-IA) and intravenous high-dose cisplatin chemoradiation without sodium thiosulfate (CRT-IV)." | 5.12 | Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. ( Balm, AJ; Dreschler, WA; Hart, AA; Lansdaal, PE; Rasch, CR; Schornagel, JH; Simis, YJ; Zuur, CL, 2007) |
| " Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment." | 2.94 | Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. ( Hu, QY; Keilty, J; Kropp, J; McCarthy, R; Ren, Y; Shi, F; Soglia, J; Viglietta, V; Weber, P; Wolff, H, 2020) |
| "Our trial suggests that STS deposited on the round window was safe for the middle and inner ears." | 2.90 | A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. ( Bairati, I; Bussières, R; Côté, M; Guitton, MJ; Leclerc, M; Meyer, F; Philippon, D; Rolland, V, 2019) |
| "Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event." | 2.66 | Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. ( Brock, PR; Cabral, S; Chang, KW; Dupuis, LL; Epelman, S; Freyer, DR; Knight, K; Mills, D; Phillips, R; Potter, E; Risby, D; Robinson, PD; Simpkin, P; Sullivan, M; Sung, L, 2020) |
| "The Children's Oncology Group (COG) Cancer Control and Supportive Care Neurotoxicity Subcommittee therefore conducted a survey of providers at COG institutions to determine perspectives on pediatric otoprotection practices and research surrounding three major themes: (1) prevalence of routine use of STS with cisplatin-based regimens, (2) application of audiometry to cisplatin therapy, and (3) preferred modalities for otoprotection research." | 1.56 | Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. ( Dvorak, CC; Esbenshade, AJ; Freyer, DR; Hardy, KK; Orgel, E; Thomas, SM; Ullrich, NJ, 2020) |
| "Sodium thiosulfate (STS) has been described as a protective agent against CDDP toxicity, but it also reduces CDDP's antitumoral cytotoxicity." | 1.32 | Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. ( Fetoni, A; Guitton, MJ; Lloyd Faulconbridge, RV; Puel, JL; Pujol, R; Wang, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orgel, E | 2 |
| Villaluna, D | 2 |
| Krailo, MD | 2 |
| Esbenshade, A | 1 |
| Sung, L | 4 |
| Freyer, DR | 5 |
| Brock, PR | 3 |
| Chang, KW | 1 |
| Dupuis, LL | 1 |
| Epelman, S | 1 |
| Knight, K | 2 |
| Mills, D | 1 |
| Phillips, R | 1 |
| Potter, E | 1 |
| Risby, D | 1 |
| Simpkin, P | 1 |
| Sullivan, M | 1 |
| Cabral, S | 1 |
| Robinson, PD | 1 |
| Viglietta, V | 1 |
| Shi, F | 1 |
| Hu, QY | 1 |
| Ren, Y | 1 |
| Keilty, J | 1 |
| Wolff, H | 1 |
| McCarthy, R | 1 |
| Kropp, J | 1 |
| Weber, P | 1 |
| Soglia, J | 1 |
| Boyce, AM | 1 |
| Gafni, RI | 1 |
| Ferreira, CR | 1 |
| Ullrich, NJ | 1 |
| Hardy, KK | 1 |
| Thomas, SM | 1 |
| Dvorak, CC | 1 |
| Esbenshade, AJ | 1 |
| Harao, T | 1 |
| Yamada, A | 1 |
| Kinoshita, M | 1 |
| Kamimura, S | 1 |
| Moritake, H | 1 |
| Duinkerken, CW | 1 |
| de Weger, VA | 1 |
| Dreschler, WA | 2 |
| van der Molen, L | 1 |
| Pluim, D | 1 |
| Rosing, H | 1 |
| Nuijen, B | 1 |
| Hauptmann, M | 1 |
| Beijnen, JH | 1 |
| Balm, AJM | 1 |
| de Boer, JP | 1 |
| Burgers, JA | 1 |
| Marchetti, S | 1 |
| Schellens, JHM | 1 |
| Zuur, CL | 2 |
| Maibach, R | 2 |
| Childs, M | 1 |
| Rajput, K | 1 |
| Roebuck, D | 1 |
| Sullivan, MJ | 2 |
| Laithier, V | 1 |
| Ronghe, M | 1 |
| Dall'Igna, P | 1 |
| Hiyama, E | 1 |
| Brichard, B | 1 |
| Skeen, J | 1 |
| Mateos, ME | 1 |
| Capra, M | 1 |
| Rangaswami, AA | 1 |
| Ansari, M | 1 |
| Rechnitzer, C | 1 |
| Veal, GJ | 1 |
| Covezzoli, A | 1 |
| Brugières, L | 1 |
| Perilongo, G | 1 |
| Czauderna, P | 1 |
| Morland, B | 1 |
| Neuwelt, EA | 4 |
| Killock, D | 1 |
| Frazier, AL | 1 |
| Rolland, V | 1 |
| Meyer, F | 1 |
| Guitton, MJ | 2 |
| Bussières, R | 1 |
| Philippon, D | 1 |
| Bairati, I | 1 |
| Leclerc, M | 1 |
| Côté, M | 1 |
| Ishikawa, E | 1 |
| Sugimoto, H | 1 |
| Hatano, M | 1 |
| Nakanishi, Y | 1 |
| Tsuji, A | 1 |
| Endo, K | 1 |
| Kondo, S | 1 |
| Wakisaka, N | 1 |
| Murono, S | 1 |
| Ito, M | 1 |
| Yoshizaki, T | 1 |
| Chen, L | 1 |
| Bliss, B | 1 |
| Pollock, BH | 1 |
| Ramdas, J | 1 |
| Lange, B | 1 |
| Van Hoff, D | 1 |
| VanSoelen, ML | 1 |
| Wiernikowski, J | 1 |
| Berglin, CE | 1 |
| Pierre, PV | 1 |
| Bramer, T | 1 |
| Edsman, K | 1 |
| Ehrsson, H | 1 |
| Eksborg, S | 1 |
| Laurell, G | 1 |
| Blakley, BW | 2 |
| Cohen, JI | 1 |
| Doolittle, ND | 1 |
| Muldoon, LL | 1 |
| Campbell, KC | 1 |
| Dickey, DT | 1 |
| Wang, J | 1 |
| Lloyd Faulconbridge, RV | 1 |
| Fetoni, A | 1 |
| Pujol, R | 1 |
| Puel, JL | 1 |
| Viallet, NR | 1 |
| Begleiter, A | 1 |
| Leith, MK | 1 |
| Simis, YJ | 1 |
| Lansdaal, PE | 1 |
| Hart, AA | 1 |
| Schornagel, JH | 1 |
| Rasch, CR | 1 |
| Balm, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons[NCT04478292] | Phase 3 | 330 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma[NCT00652132] | Phase 3 | 116 participants (Actual) | Interventional | 2007-12-15 | Completed | ||
| A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children[NCT00716976] | Phase 3 | 131 participants (Actual) | Interventional | 2008-06-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in hearing threshold (post-pre) at 1000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | -0.676 |
| Observation Arm | -0.319 |
Mean change in hearing threshold (post-pre) at 2000 hz (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | -1.18 |
| Observation Arm | 0.638 |
Mean change in hearing threshold (post-pre) at 4000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 1.05 |
| Observation Arm | 9.58 |
Mean change in hearing threshold (post-pre) at 500 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | -1.45 |
| Observation Arm | -1.11 |
Mean change in hearing threshold (post-pre) at 8000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 9.73 |
| Observation Arm | 17.0 |
Proportion of patients event free at 4 years following enrollment. See EFS outcome measure description. (NCT00716976)
Timeframe: 4 years after enrollment
| Intervention | Percentage probability (Number) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 53.7 |
| Observation Arm | 61.4 |
Hearing loss defined by comparing hearing sensitivity at follow up evaluation relative to baseline measurements using ASHA criteria. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Patients (Number) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 14 |
| Observation Arm | 31 |
Proportion of patients alive free at 4 years following enrollment. See OS outcome measure description. (NCT00716976)
Timeframe: 4 Years after enrollment
| Intervention | Percentage probability (Number) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 69.6 |
| Observation Arm | 82.0 |
2 reviews available for thiosulfates and Deafness, Transitory
| Article | Year |
|---|---|
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Topics: Adolescent; Antineoplastic Agents; Child; Cisplatin; Female; Hearing Loss; Humans; Male; Neoplasms; | 2020 |
Generalized Arterial Calcification of Infancy: New Insights, Controversies, and Approach to Management.
Topics: Adenosine Monophosphate; Bone Density Conservation Agents; Calcinosis; Cardiovascular Agents; Chelat | 2020 |
6 trials available for thiosulfates and Deafness, Transitory
| Article | Year |
|---|---|
Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Topics: Adult; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Healthy Volunteers; Hearing Lo | 2020 |
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Topics: Adult; Antineoplastic Agents; Cisplatin; Hearing Loss; Humans; Thiosulfates | 2021 |
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll | 2018 |
A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Topics: Aged; Antineoplastic Agents; Antioxidants; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Nec | 2019 |
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C | 2017 |
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C | 2017 |
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C | 2017 |
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C | 2017 |
Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Topics: Antineoplastic Agents; Auditory Threshold; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Th | 2007 |
12 other studies available for thiosulfates and Deafness, Transitory
| Article | Year |
|---|---|
Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431.
Topics: Cisplatin; Hearing Loss; Humans; Thiosulfates | 2022 |
Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey.
Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Cisplatin; Follow-Up Studies; Hearing Loss; | 2020 |
Prevention of cisplatin-induced hearing-loss by sodium thiosulfate in medulloblastoma.
Topics: Antineoplastic Agents; Cerebellar Neoplasms; Cisplatin; Hearing Loss; Humans; Medulloblastoma; Thios | 2020 |
Sodium thiosulfate halves the risk of cisplatin-induced hearing loss.
Topics: Cisplatin; Hearing Loss; Humans; Thiosulfates | 2018 |
Sodium Thiosulfate and Cisplatin-Induced Hearing Loss.
Topics: Antineoplastic Agents; Cisplatin; Deafness; Hearing Loss; Humans; Thiosulfates | 2018 |
Sodium Thiosulfate and Cisplatin-Induced Hearing Loss.
Topics: Antineoplastic Agents; Cisplatin; Deafness; Hearing Loss; Humans; Thiosulfates | 2018 |
Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chelating Agents; Chemorad | 2015 |
Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Topics: Amifostine; Cisplatin; Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Inter | 2009 |
Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model.
Topics: Animals; Antineoplastic Agents; Cisplatin; Ear, Middle; Female; Gels; Guinea Pigs; Hair Cells, Audit | 2011 |
Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001.
Topics: Animals; Antineoplastic Agents; Antioxidants; Blood-Brain Barrier; Carboplatin; Cisplatin; Head and | 2002 |
Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig.
Topics: Action Potentials; Animals; Cell Death; Cisplatin; Cochlea; Cytochrome c Group; Female; Guinea Pigs; | 2003 |
Effect of sodium thiosulphate and cis-diamminedichloroplatinum on FADU tumour cells in nude mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Squamous Cell; Cisplatin; Disease Models, A | 2005 |